According to the American Society of Nephrology, Kidney Week 2012 is “the world's premier nephrology meeting. More than 13,000 kidney professionals from around the globe will come together to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative exchanges between leading experts in the field.”
Results from the TEMPO trial presented at Kidney Week 2012 show that treatment with tolvaptan slowed the increase in total kidney volume and the decline in kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Randomized controlled trials remain the gold standard, but a researcher at Kidney Week 2012 says that new approaches and study designs are needed that reflect real-world drug use and account for confounding variables.
Increasing numbers of people are on kidney transplant waiting lists. However, the number of potential living donors may shrink as more Americans qualify as pre-diabetic, making them less than ideal donor candidates.
The powerful immunosuppressive drugs used to prevent allograft rejection are associated with severe side effects. A “mixed chimerism” strategy in which patients undergo simultaneous bone marrow and kidney transplant from the same donor may improve transplant survival and reduce the need for these drugs.